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Abstract:
Background: Maintain Your Brain (MYB) is a randomized controlled trial of an online multi-modal lifestyle intervention
targeting modifiable dementia risk factors with its primary aim being to reduce cognitive decline in an older age cohort.
Methods: MYB aims to recruit 8,500 non-demented community dwelling 55 to 77 year olds from the Sax Institute’s 45 and
Up Study in New South Wales, Australia. Participants will be screened for risk factors related to four modules that comprise
the MYB intervention: physical activity, nutrition, mental health, and cognitive training. Targeting risk factors will enable
interventions to be personalized so that participants receive the most appropriate modules. MYB will run for three years and
up to four modules will be delivered sequentially each quarter during year one. Upon completing a module, participants will
continue to receive less frequent booster activities for their eligible modules (except for the mental health module) until the
end of the trial.
Discussion: MYB will be the largest internet-based trial to attempt to prevent cognitive decline and potentially dementia.
If successful, MYB will provide a model for not just effective intervention among older adults, but an intervention that is
scalable for broad use.
Keywords: Alzheimer’s disease, clinical trial, cognitive decline, cognitive training, dementia, depression, non-
pharmacological, physical activity, nutrition, randomized controlled trial
Trial registration: ACTRN 12618000851268. Registered on the Australian New Zealand Clinical Trials Registry (http://
www.anzctr.org.au).
INTRODUCTION
Dementia affects approximately 44 million peo-
ple worldwide [1] and assuming the status quo is
projected to expand to over 136 million by 2050
[1, 2]. Globally, it is a leading cause of disability
with costs estimated to exceed 800 billion dollars
[1]. In the next 40 years, these costs are projected
to exceed those of all other chronic diseases [3]. In
light of the modest efficacy of symptomatic drugs for
Alzheimer’s disease and the lack of success in tri-
als of disease-modifying medications, interventions
to delay onset and possibly prevent dementia have
gained momentum [4]. Given that dementia has a
multifactorial etiology, multi-domain interventions
are arguably more likely to be effective in delay-
ing onset [5, 6]. However, evidence for the benefits
of multiple combined interventions such as physical
activity and cognitive training is limited [7, 8].
In the FINGER (Finnish Geriatric Intervention
Study to Prevent Cognitive Impairment and Dis-
ability) trial a multi-modal intervention (physical
activity, diet, and cognitive training) was effective
at reducing cognitive decline in a group of 60 to
77 year olds at risk of dementia and with average
or below cognitive scores [9]. Two other trials, the
Multidomain Alzheimer Preventive Trial (MAPT)
and the Prevention of Dementia by Intensive Vas-
cular care (PreDIVA), reported encouraging results
in post-hoc or subgroup analyses [10, 11]. Impor-
tantly, a limitation of both FINGER and PreDIVA
was their requirement for clinic attendance that
would restrict large scale deployment should positive
results on clinically meaningful outcomes be found.
Internet delivered interventions have the potential
to overcome some of the limitations of traditional
face-to-face interventions, in that the former are scal-
able, can reach geographically isolated individuals,
are convenient (e.g., can be undertaken at home), and
are cost effective.
We therefore designed an internet-delivered multi-
domain preventative intervention—Maintain Your
Brain (MYB)—to target multiple risk factors for
dementia in general and AD in particular. Tar-
geted risk factors are physical inactivity, sub-optimal
dietary patterns, cognitive inactivity, depression, anx-
iety, and health-related issues implicated in dementia
risk such as overweight, obesity, excess alcohol con-
sumption, smoking, and chronic health conditions.
The MYB program is organized into four differ-
ent modules—Physical Activity, Nutrition, Peace of
Mind. and Brain Training—each of which is cus-
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tomized to a person’s individual risks. MYB builds
upon previous trials but introduces novel elements
and state-of-the-art concepts in mode of delivery and
behavioral change theory to make it unique. Other
advantages of MYB are that it is comprehensive
in addressing risk factors and it will be one of the
first prevention trials to address depression. Modules
are also responsive to individual participant progress
rather than a one-size-fits-all approach. The program
will initially deploy interventions sequentially and
then build up booster sessions over time, minimiz-
ing the possibility of interference or over-dose effects
[12, 13]; it introduces innovations in computer-based
cognitive training including insights from gaming,
remote supervision, social support, and coaching
when required. Finally, the randomized controlled
trial (RCT) will be larger than previous studies allow-
ing for sub-analyses of subsidiary questions
MYB aims to: 1) in the short term, develop
a new MYB digital platform that delivers multi-
modal, personalized, and sequential modules that
target dementia risk factors via the Internet; 2) in the
medium term, evaluate the efficacy of the MYB dig-
ital platform to reduce the rate of cognitive decline
in non-demented community dwelling persons aged
55 to 77 years; 3) to examine the impact on reduc-
tion in risk factors, improvement in specific module
targets (physical activity, nutrition, depression, indi-
vidual cognitive domains); and 4) evaluate the relative
cost effectiveness of the platform.
The primary hypothesis of MYB is that over
three years of intervention participants engaging with
coaching (intervention) modules on the MYB digi-
tal health platform will have less cognitive decline
than the information only control group. Secondary
hypotheses are that there will be less incident all-
cause dementia than the control group; a relationship
between intervention fidelity (compliance and adher-
ence) and cognitive outcomes; there will be less
categorical cognitive impairment in the intervention
group compared to the control; dementia risk profile
will improve significantly more in the intervention
group; and such a risk profile improvement will cor-
relate with better cognitive outcomes.
METHODS
Design
MYB is an online single-blind randomized con-
trolled trial (Australian New Zealand Clinical Trials
Registry ACTRN 12618000851268) of a person-
alized, multi-modal intervention designed to target
modifiable risk factors for Alzheimer’s disease and
dementia. Risk factors to be addressed include
physical inactivity, poor diet, cognitive inactivity,
depression/anxiety, and chronic diseases and habits
(alcohol, smoking) linked to dementia risk. Up to
four intervention modules (physical activity, nutri-
tion, peace of mind, and brain training) will be
administered based on individual risk profiles. Each
module will be initially delivered using the MYB
digital platform over 10 weeks. In the first year of
the RCT, participants will complete their assigned
modules sequentially, noting that the total number
of modules varies depending on the respective indi-
vidual’s risk factors. In practice, this will translate
to a minimum of two modules and a maximum of
four modules. Upon completing a module, booster
sessions (specific to each module) and ongoing mon-
itoring will then continue for up to three years.
Follow-up assessments measuring these risk factors
and cognition will be completed annually for three
years. The control group (“information” group) will
receive basic psychoeducation about dementia risk
factors accessed through the MYB digital platform.
Set activities will be organized by corresponding
module eligibility and also themed into the same
modules of physical activity, nutrition, peace of mind,
and brain training. Control participants will not be
receiving any module-related tailored advice (i.e., the
“coaching” component in intervention). They will
otherwise undertake the same enrolment, baseline
and annual follow-up assessments. An overview of
participant flow through the trial is provided in Fig. 1.
Owing to the nature of the intervention, par-
ticipants and research staff involved in delivering
modules will not be blind to allocation. However,
the MYB digital platform is an automated system
with all activities and assessments delivered elec-
tronically without researcher intervention (unless a
participant has requested to be withdrawn or for
safety). Researchers responsible for analyses will be
blinded to group allocation and analyses will be com-
pleted (as much as possible) without the use of data
that may incidentally unblind the analysis (e.g., mod-
ule allocation, types of completed activities).
Setting
MYB is online and all study procedures will be
delivered and managed via the MYB digital platform.
Participants will access all trial materials and associ-
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Fig. 1. MYB trial flowchart.
ated help by logging into the MYB digital platform.
Personalized activities, with due dates, reminders,
and progress will be available through this online plat-
form. MYB will be supported by a team of researchers
who will provide technical assistance to participants.
Each module is led and supported by experienced
researchers with relevant expertise in delivering their
respective interventions.
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Recruitment and selection of participants
Participants will be recruited from the Sax Insti-
tute’s 45 and Up Study [14]. From January 2006 to
December 2009, men and women from the general
population of New South Wales (NSW), Australia
were sampled through the Department of Human
Services (formerly Medicare Australia) database
and joined the study by completing a postal ques-
tionnaire. Participants provided written informed
consent for follow-up through repeated contact and
linkage to population health databases. A total of
267,153 people, about 1 in every 10 NSW men and
women aged over 45, are participating in the 45
and Up Study, making it the largest ongoing study
of healthy aging in the Southern Hemisphere. Now
8–11 years after recruitment, participants are aged
53 years and up. The 45 and Up Study is among
the most heterogeneous large-scale cohort studies
internationally, with participants from diverse socio-
demographic, geographic, and cultural backgrounds,
which will increase the likelihood that any cogni-
tive effects or risk reduction observed in the trial are
generalizable to other populations.
Invitations will be sent by the 45 and Up Study
electronically and by mail to potential MYB par-
ticipants. Participants will not receive both types of
invitations. As MYB, being fully online, requires par-
ticipants to have an email address to be able to login
and receive notifications; electronic invitations will
be prioritized over physical mail. Invitations sent by
email or mail will be identical, except that a unique
registration link cannot be sent with the physical mail.
Participants receiving mailed invitations will need
to enter an email address to be able to receive the
unique registration link. All subsequent registration
procedures will be identical.
Participants will be eligible to receive invitations if
they are enrolled in the 45 and Up Study, have agreed
to be contacted about further studies, are aged 55 to
77 years on the first day of the year recruitment com-
mences, do not have dementia, Parkinson’s disease,
or multiple sclerosis (based on available 45 and Up
records) and did not participate in any previous MYB
validation or pilot studies.
Participants who provide consent and register on
the MYB digital platform will complete a brief
screening tool developed for the MYB trial. Par-
ticipants will be excluded if they: do not respond
to the invitation (one reminder may be sent); are
unwilling or unable to access trial tasks on the
MYB digital platform; are involved in another inter-
vention trial involving exercise, brain training, diet,
depression/anxiety treatment, or any drug/nutritional
supplement trial; do not have home internet or
computer access (desktop or laptop); have vision
problems which prevent them from reading a com-
puter screen or are otherwise unable to use a
mouse/keyboard without assistance; have a life
threatening condition; have any dementia, Parkin-
son’s disease, or multiple sclerosis; have ever been
prescribed a medication used to treat Alzheimer’s dis-
ease; have been hospitalized overnight (≥24 h) more
than 6 times in the past 12 months; report having had
a stroke or heart attack in the previous 3 months; have
been diagnosed with brain cancer; have any form of
current malignancy other than cancer that has been in
remission for at least 5 years (and does not currently
require continuing chemotherapy), or non-metastatic
prostate or skin cancer; have ever been diagnosed
with bipolar disorder or schizophrenia; have severe
depression (Patient Health Questionnaire [15], PHQ9
total score >19); report having suicidal intent (PHQ-9
item 9 >1 and Beck Depression Inventory [16] item
9 >1); are unable to write/converse in English; do not
have at least two unique risk factors and are not eligi-
ble for at least two modules (risk factors determined
after baseline assessment).
Participants who are eligible for the trial will then
complete baseline assessments used to assess their
risk factors and module eligibility. Participants will
be enrolled if they complete all baseline assessments
(by the MYB start date) and have at least two unique
risk factors and are eligible for at least two modules.
Randomization
Participants who provide informed consent, meet
trial inclusion criteria and none of the exclusion cri-
teria, and complete all baseline assessments will be
enrolled in the trial. Participants agreeing to be in
MYB will be randomized (1:1 allocation ratio) using
the minimization technique [17] based on the follow-
ing stratification variables:
• Age (55–65 years; 66–77 years) as of
01/01/2018
• Gender (male, female)
• Dementia risk as measured by Australian
National University Alzheimer’s Disease Risk
Index Short Form [18] (tertiles total risk score)
• Module eligibility (1 module; 2 modules; 3 mod-
ules; 4 modules)
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Per the minimization technique, a weighted-
coefficient variable is used to assign the participants
within each profile into intervention and control
groups (1:1 allocation ratio). Randomization will
occur after baseline assessments have been com-
pleted and therefore after module eligibility has
been determined. We will conceal allocation with
randomization performed centrally by a computer-
ized process and activities are then automatically
delivered to participants through the MYB digital
platform.
Module eligibility
Participants who are otherwise eligible for the trial
will be assessed for module eligibility using baseline
assessments (i.e., prior to randomization). Each mod-
ule is designed to address a known dementia risk and
therefore criteria are unique to each of the modules
(see below). Module rules are built into the MYB
platform and applied automatically. Researchers can-
not override this pre-set decision algorithm except in
cases of safety where participants may be removed
from a module should they reveal, as the trial pro-
gresses, a new health issue not disclosed or present
at baseline, or they withdraw consent.
Participants with only one unique risk factor and
hence eligible for less than two modules will be
allowed to enter in MYB, however, only participants
with at least two unique risk factors and eligible for
at least two modules will be included in the planned
primary MYB analyses. This means if a participant
has only one risk factor, such as high blood pressure,
which makes them eligible for two modules (such
as physical activity and nutrition) they will not be
included in the primary analysis.
Individual module eligibility
Physical activity (PA)
Participants will be eligible for the PA module
based on health conditions identified in the Aus-
tralian National University Alzheimer’s Disease Risk
Index Short Form (ANU-ADRI-SF [18, 19], medical
history (MYB Medical History), and MYB Physi-
cal Assessment battery (includes measures of body
composition, Harvard Alumni Questionnaire [20],
International Physical Activity Questionnaire [21]
sitting, and Virtual Short Physical Performance Bat-
tery Protocol [22]). Risks identified include low levels
of physical activity (aerobic and/or resistance train-
ing), high levels of sitting, high blood pressure,
dyslipidemia, diabetes, heart related issues, stroke,
transient ischemic attack (TIA), high body mass
index (BMI), high waist circumference, and active
smoking status. Participants will be excluded from
the PA module (but not the trial) if they report any
health concerns that would make continuing in this
module unsafe. This includes being advised not to
exercise by a health professional, worsening angina in
the previous three months, angina at times other than
moderate to vigorous activity, unrepaired aneurysms
and 12 or more seizures in the previous 12 months.
Nutrition
Participants will be eligible for the Nutrition
module based on health conditions identified in
the MYB Medical History or a dietary assess-
ment using the Mediterranean Diet and Culinary
Index (MediCul). Medicul is a newly created diet
assessment for the Mediterranean diet [23] from
which a score for the Mediterranean Diet Adher-
ence Screener (MEDAS) [24] is also derived.
MEDAS was selected as it is used in PRED-
IMED (Prevencio´n con Dieta Mediterra´nea), the
largest clinical trial on the Mediterranean diet,
and has been associated with cognitive outcomes
[25, 26]. A MEDAS score of nine or less indi-
cates low adherence with a Mediterranean dietary
pattern. Other risks identified include high blood
pressure, high cholesterol, diabetes, heart related
issues, stroke, TIAs, peripheral vascular disease,
BMI, waist circumference, and excessive alcohol
consumption.
Peace of mind
Participants who currently meet probable criteria
for unipolar depression and/or an anxiety disorder as
assessed by their total Patient Health Questionnaire
(PHQ-9) [15] and/or Generalized Anxiety Disorder-
7 (GAD-7) [27] scores; and/or report having been
diagnosed and/or treated for unipolar depression or
their anxiety during their lives (MYB Medical His-
tory) will be eligible for the “ThisWayUp Mixed
Depression and Anxiety” course (e.g., see https://this
wayup.org.au).
Brain training
Participants will be eligible for Brain Training
based on years of education (ANU-ADRI-SF), or
lower than average late life mental activity (Life
Experiences Questionnaire, LEQ late life subscale
subthreshold [28]) or mental activity during mid-life
(LEQ midlife sub scores subthreshold).
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Sequencing of modules
The order that participants will receive modules
is determined by a pseudo-random process (Sup-
plementary Material 1). This process is carried out
automatically by the MYB digital platform once a
participant has completed all baseline assessments,
module eligibility has been determined and prior to
randomization.
Interventions
Coaching (intervention)
The MYB intervention comprises up to four 10-
week modules delivered quarterly in the first 12
months of the trial, with monthly boosters for mod-
ules where appropriate thereafter. These modules
are Physical Activity, Nutrition, Peace of Mind,
and Brain Training. All procedures described will
be accessed through the MYB digital platform. All
modules will begin with a brief module expectations
questionnaire and end with a brief questionnaire mea-
suring participants’ appraisal of the module.
Physical activity (PA)
The basic PA prescription is designed to increase
aerobic and resistance training to levels with a demon-
strated positive impact on cognition and other health
outcomes [29, 30]. Where feasible, the module will
support progression to higher exercise intensities
as this is linked to improved risk reduction, fitness
outcomes and cognition in observational and exper-
imental studies [31, 32]. In addition, daily balance
training exercises and information on smoking ces-
sation will be included. A behavioral change program
[33] is integrated within the PA module by providing
personalized goals and feedback, and by encouraging
activity logging.
The PA module is fully online and provided
through the PA portal on the MYB digital platform.
All goals, feedback, and materials (e.g., videos, fact-
sheets) are arranged around three exercise modalities:
aerobic exercise, resistance training, and balance
training. Information is provided to support achieve-
ment of the long-term goal of 300 min/week of
moderate to vigorous intensity aerobic activity, three
days/week of vigorous intensity progressive resis-
tance training, and challenging balance training every
day. Behavioral change is integrated within the mod-
ule through updating feedback and goals. These are
personalized based on activity logged by the partici-
pant (weekly self-report via Short Physical Activity
Assessment). Feedback is responsive to both partic-
ipants who are improving (for example, providing
updated goals) and participants who are not pro-
gressing or are regressing. If a lack of progression is
detected, the module will direct participants to infor-
mation on barriers and how to overcome them, as
well as how exercise can be modified for pain or
injury. Participants are also encouraged to use the
online Action Plan to write how their goals will be
achieved. Feedback on progress is displayed to par-
ticipants visually (via a virtual “staircase”) for each
of the three exercise modalities. Short term goals and
feedback will follow the general approach of starting
exercise at low frequencies and intensities for those
not currently exercising and then reaching the tar-
get volume within the first month. Once the desired
volume is reached, intensity goals will be addressed
aiming to reach these by the end of the 10-week mod-
ule. Progression from moderate to vigorous aerobic
and resistance training activities will be encouraged
as feasible based on their logged behavior which
includes modality, volume, frequency, and perceived
intensity (Borg Scale of Perceived Exertion). Partici-
pants will be encouraged to add dual tasking to their
balance exercises once they have achieved daily bal-
ance practice and reached the most challenging level
of each exercise. Balance intensity is advanced by
gradual reduction of hand support and visual input
during static and dynamic exercises. After the initial
10 weeks of the intervention, booster or “refresher”
sessions will be added. Booster sessions are identical
to module activities but occur less frequently (every
four weeks for up to three years follow-up) to allow
internalization of monitoring and progression.
All materials are developed by qualified exercise
physiologists and/or physiotherapists and provided
on the MYB digital platform. Content can be accessed
as many times as the participant wishes and will also
cover topics related to behavioral change, chronic dis-
eases, relapse prevention, progression, variety, and
long-term adherence. All materials can be updated,
removed, and new materials added. The PA module
is designed to be self-administered, with participants
able to engage with materials in their own time.
During the module and follow-up, participants will
also be able to contact “module trainers” (qualified
exercise physiologists or physiotherapist) with ques-
tions or issues related to the module. This contact
will initially be via the online interface, with follow-
up contact as appropriate (e.g., email and phone).
Module trainers will also update “Frequently asked
questions” factsheets for triaging common problems
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and questions arising during exercise adoption, refer
participants to their GP for suspected exercise-related
or other injury, recurrent falls, potential medication-
related side effects, or instability /progression of
underlying chronic diseases such as osteoarthritis,
angina, etc.
The PA module will be adjusted if a participant
reports being diagnosed with osteoporosis, or a high
number of falls in the past 12 months, or scores poorly
in the virtual Short Physical Performance Battery
(vSPPB) [22] by removing any goals and feedback
related to aerobic exercise as walking may increase
risk of falls until strength and balance are improved
[34, 35]. During annual assessments, participants
could be reallocated to the main PA module if appro-
priate. Initially, baseline assessments will be used
to exclude any participant from PA owing to safety
concerns (for example, being advised by a medical
professional not to exercise). Participants who are
eligible for PA at baseline may subsequently report
a health concern that requires adjustment to their PA
module. The aerobic component of the module can
be removed based on pre-set rules applied automati-
cally by the MYB digital platform (for example too
many reported falls). Their PA module can also be
temporarily blocked (or ‘unblocked’ if recovered) on
a case-by-case basis by qualified PA module staff
(e.g., clinicians and exercise physiologists). For any
health-related concern that is not planned or reported
via the MYB platform, researchers may inform the
MYB administrator to remove participants from the
module entirely.
Physical activity logged via the Short Physical
Activity Assessment (weekly in the first 10 weeks,
then monthly) will be used to measure PA/sedentary
behavior levels during the module. These weekly log-
ging tasks, email notifications about new tasks as well
as intermittent newsletters will be used to support
adherence to the module. Whether a participant com-
pletes activity logs and action plans, and how many
times they visit the PA module can be used to assess
engagement with the module.
Nutrition
The Nutrition module is designed to encourage
adoption of a Mediterranean diet acknowledged in
dietary guidelines as a healthy eating pattern for
chronic disease [36, 37]. The rationale for this diet
is based on its relevance to risk factors for cognitive
decline and RCT and prospective cohort data for a
Mediterranean diet [38–41]. At this time, the Mediter-
ranean diet appears to be the most strongly supported
dietary pattern for cognitive benefits in clinical trials
[41].
The Nutrition module is fully online and pro-
vided through the Nutrition portal on the MYB
digital platform. All dietary messages, feedback,
and materials (such as cooking videos, meal plans,
recipes, shopping lists, health tips, factsheets, and
behavioral change resources) are arranged around
10 food groups (discretionary foods, animal pro-
tein, extra virgin olive oil, nuts, vegetables, fruit,
legumes, wholegrains, fish and seafood, and water)
within the Mediterranean diet to provide smaller
manageable targets for change. The Nutrition portal
provides a visual display of the Mediterranean diet
that participants are aiming to achieve (via an ideal
“Mediterranean diet food pyramid”) based on their
self-reported food intake. Food intake will be via the
MiniCul, a screener form of the MediCul [23] that is
used to prompt behavior change within the module.
The components of the Mediterranean diet food pyra-
mid will be completed in sections, with personalized
messages and feedback provided for food groups
that require improvement. Although personalized, the
overall approach of dietary messages and feedback is
to target the most poorly scored and crucial changes
first. Additionally, participants will only receive a
manageable number of changes each week (maxi-
mum four messages). If a participant does not make
any changes for two weeks (as measured by weekly
online food intake logging), messages will move onto
other poorly scored food groups and cycle back to
the unchanged groups if time is available. There-
fore, even a participant who needs to make changes
across all 10 food groups but shows no change in
their weekly log, will receive advice and recommen-
dations for all food groups. If a participant reaches
the ‘ideal’ Mediterranean diet food pyramid they
will be encouraged to maintain their Mediterranean
diet.
The initial Nutrition module is delivered over 10
weeks during the first 12 months of MYB. During the
first 10 weeks participants are encouraged to log their
adherence to the Mediterranean diet weekly (self-
report via MiniCul). Participants are also encouraged
to fill out a weekly action plan for how they will
improve their Mediterranean diet score for each of the
suggested food changes. After the initial 10 weeks of
intervention, booster sessions will be added. Proce-
dures and materials for booster sessions are identical
to the initial Nutrition module. However, booster
sessions and therefore diet logging will occur less
frequently (every 4 weeks).
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All materials are designed by qualified dietitians
and can be accessed as many times as the par-
ticipant wishes. Materials include recipes, videos,
shopping lists, and factsheets. Topics covered by
these materials will be related to the recommended
diet as well as areas such as behavioral change, sci-
entific literature, special dietary considerations and
food allergies, intolerances and drug interactions. All
materials can be updated, removed,and new materials
can be uploaded by the Nutrition module staff (i.e.,
qualified dietitians).
The Nutrition module is designed to be self-
administered with participants able to engage with
the materials in their own time. During the mod-
ule and follow-up, participants will also be able to
contact “module trainers” (qualified dietitians) with
questions or issues related to the module. This contact
will initially be via the online interface, with follow-
up contact as appropriate (e.g., email and phone).
Module trainers will also provide updates to “Fre-
quently asked questions” and refer participants to a
GP if necessary.
There are two planned modifications to the Nutri-
tion module based on alcohol consumption and being
underweight. If participants report a high rate of
alcohol consumption, diet messages related to alco-
hol will be prioritized and remain until participants
report a reduced alcohol intake. Participants report-
ing low body weight will receive modified advice
that encourages adapted serving sizes compared to
the main Nutrition module. After the 10-week inter-
vention, such participants could be reallocated to
the main Nutrition module if goals are achieved.
Likewise, participants receiving the main Nutrition
module could be reallocated to the modified alcohol
or underweight Nutrition module after the 10-week
intervention if appropriate. These modifications are
pre-set and the rules are applied automatically by
the MYB digital platform. For any other diet-related
concerns, such as medical advice not to alter their
diet, researchers may remove participants from the
module entirely if it becomes unsafe for them to con-
tinue. However, there is flexibility to allow for food
preferences, financial circumstances, special dietary
requirements, food allergies, intolerances, and ethnic
backgrounds.
The MiniCul is used weekly in the first 10
weeks, then monthly, to track progress with adopt-
ing a Mediterranean diet during the intervention.
In addition, self-reported body measurements (waist
circumference, weight) are also checked during
this module. Weekly email reminders to complete
MiniCul and intermittent newsletters to support
adherence to the module are also provided. Engage-
ment with the Nutrition module is tracked by the
number of completed MiniCuls, action plans to
achieve Mediterranean goals and the number of times
participants login.
Peace of mind
Participants who are currently depressed and/or
anxious; and/or have ever been diagnosed/treated
for depression and/or anxiety will have access to
the “ThisWayUp Mixed Depression and Anxiety”
course. This course has been developed by the
Clinical Research Unit for Anxiety and Depression
(CRUfAD) at UNSW/St Vincent’s Hospital and the
efficacy and effectiveness of the program reported
previously [42–44]. During the module, participants
will be able to contact CRUfAD staff with clinical
and technical questions.
The Mixed Depression and Anxiety course
includes six lessons delivered over 10 weeks. These
lessons include: 1) Psychoeducation about anxiety
and depression, identifying symptoms, the fight or
flight response, controlled breathing and physical
activity/exercise; 2) Cognitive therapy components:
education about the cognitive model, cognitive dis-
tortions, and introduction to thought monitoring;
activity planning; 3) Thought challenging/cognitive
restructuring; challenging positive & negative meta-
cognitive beliefs about repetitive thinking; shifting
attention, hunt for positives; 4) Education about
avoidance and safety behaviors; graded expo-
sure and structured problem solving; 5) Advanced
graded exposure (imaginal exposure, interoceptive
exposure); troubleshooting difficulties with graded
exposure; and 6) Relapse prevention. There are
no boosters associated with the Peace of Mind
module.
Participants’ completion of each lesson will be
used to assess adherence to the module. During the
module, participants will complete measures of: psy-
chological distress at the start of each lesson (Kessler
Psychological Distress Scale, K10) [45]; and depres-
sion (PHQ-9) [15] and anxiety symptom severity
(GAD-7) [27] prior to lessons 1, 4, and 6.
Brain training
Participants with an at-risk cognitive profile will
be eligible for the Brain Training module. Partici-
pants will complete a personalized cognitive training
program that is vertically and horizontally adaptive
called the “Brain Training System” (BTS). That
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is, the training regimen is defined on participant’s
baseline cognitive profile and continues to evolve
in response to within-training task performance.
Individual cognitive exercises are run as Flash files
as provided by our commercial partner (Synaptikon,
trading as NeuroNation, Germany); more than 30
are available at the outset and will be supplemented
throughout the trial. BTS has otherwise been orig-
inally designed, including the approach to exercise
selection, streaming, feedback, coaching, and social
support.
A participant’s cognitive profile is generated
based on cognitive tests completed at baseline.
These profiles will rank performance across cogni-
tive domains (i.e., verbal executive, speed, verbal
memory, visual executive, visual memory, visual
attention) in descending order. The initial exercise
selection and streaming order will reflect this profile,
preferentially targeting areas of weakness in the mid-
dle of the session. Exercise selection and streaming
will be recalibrated during training several times, in
this case based on degree of improvement on exer-
cises at the domain-level.
Exercises will be presented as three sessions per
week, translating to 30 sessions over 10 weeks. Each
session will last 45 minutes and comprise 17 exer-
cises. If participants miss sessions, they will remain
available until completed. During follow-up, booster
exercises will be offered once a month (up to three
years follow-up). Cognitive training materials (e.g.,
factsheets) will also be provided and can be accessed
as many times as the participant wishes.
After completing the first five sessions, partic-
ipants will receive a feedback performance graph
that summarizes their cognitive performance on each
cognitive domain trained thus far. This performance
graph will also indicate the range of scores for the
top 25% performers in the module based on previous
sessions. Participants’ individual performance will be
updated after completing each session and the top
25% range will be updated weekly.
In order to maximize adherence and motivation,
BTS will deploy several socialization and gaming
strategies. This includes access to an online Trainer,
prioritized for participants ‘red-flagged’ as strug-
gling with engagement or performance. Video chat
will be preferred for these interactions, but partici-
pants will also be able to contact module trainers via
MYB’s online interface. Participants can also nomi-
nate friends or family members who will be advised
via email when the participant reaches certain adher-
ence milestones, with the aim of providing social
support and encouragement and establishing a com-
munity of practice.
The Brain Training module is therefore designed to
be automatically adaptive to a participant’s baseline
score and progress during training. Safety issues are
not foreseen for this module.
Participants will receive email notifications when
a new activity is available as well as when perfor-
mance problems are noted to support adherence. The
Brain Training module will measure within-exercise
improvement, domain-level performance changes,
program adherence (completed sessions) and social
platform engagement.
Information (Control)
Participants in the control group will receive basic
health information organized in the same module
topics as the intervention (Physical Activity, Nutri-
tion, Peace of Mind, and Brain Training). Participants
will have access to these information-based modules
based on their module eligibility and in a pseudo-
random order as described in the previous section.
Although control participants receive modules based
on their individual risk profile they will not be pro-
vided with any tailored advice (i.e., the ‘coaching’
intervention component) about how to improve their
risk factors. The control group will receive infor-
mation monthly for up to four 10-week modules in
the first 12 months. All procedures described will be
delivered online and accessed through the MYB dig-
ital platform. All modules will begin with a brief
module expectations questionnaire and end with a
brief questionnaire measuring participants’ appraisal
of the module.
For the Physical Activity, Nutrition, and Peace of
Mind control modules, the information provided will
be focused on existing health guidelines and gen-
eral advice for achieving these targets. For example,
providing the Australian Dietary Guidelines from
the Australian Government Department of Health
and Ageing without specifying how participants can
achieve these guidelines. The Brain Training control
module will involve a brief task (such as showing
videos with a brief quiz). These tasks have been used
in previous trials and have been shown to be enjoyable
with minimal impact on cognition [46]. Participants
will access the 10-week modules via the MYB dig-
ital platform with new module information or tasks
provided once a month. Upon completing the Physi-
cal Activity, Nutrition, and Brain Training modules,
these activities are then reduced to quarterly (i.e.,
M. Heffernan et al. / Maintain Your Brain protocol S231
boosters) for up to three years follow-up. As with
intervention, there will be no boosters for the Peace
of Mind module.
The control group will receive periodic emails
reminding them to login to the MYB digital plat-
form to access module information. All participants
in a control module will receive the same basic health
information or task (with no tailored advice). How-
ever, they may be removed from a module for safety
reasons (e.g., a previously undisclosed/undiagnosed
health issue that might prevent safe exercise).
Engagement with the module can be measured by
the amount of times a participant logs into the MYB
eHealth platform and the amount of times they visit
the module information webpage.
Outcome measures
Primary outcome
The primary outcome is change in cognition from
baseline to three years. We will test whether the
groups show differential change over the trial as
indicated by the group by time interaction. In addi-
tion, we will test the group difference at three years
as a planned comparison. The outcome variables
are the global cognition composite domain scores,
at baseline and three years, as measured by the
MYB online cognitive test battery (“MYB Battery”).
Domains and tests in MYB are defined as: 1) Complex
attention (Cogstate Detection and Cogstate Identifi-
cation); 2) Executive Function (Cogstate One Back,
Cambridge Brain Sciences Spatial (Tokens) Search
and Cambridge Brain Sciences Grammatical Reason-
ing); and 3) Learning and Memory (Cogstate One
Card Learning and Cambridge Brain Sciences Paired
Associates). Two valid test scores per domain are
required to generate a participant’s domain score at
each time point. Individual test scores will be con-
verted to standard scores (z-scores) using the means
and standard deviations (SD) of the MYB baseline
sample. Domain scores will be calculated by first
averaging the z-scores of the component tests, and
then transforming the composite scores using the
means and SDs of the MYB baseline sample. A global
cognition score will be calculated by averaging across
the three standardized domain scores, and then the
score will be similarly transformed to z-scores using
the means and SDs of the MYB baseline sample.
Secondary outcomes
Secondary outcomes related to cognitive impair-
ment and dementia are: 1) incident dementia at three
years; 2) change in dementia risk (ANU-ADRI-SF
total score); and 3) using the method described for
the primary outcome, change in cognitive domain
scores and individual cognitive tests that form the
MYB Battery as well as LOGOS.
Dementia in MYB will be determined according
to the following:
• Participants are screened for dementia at base-
line via self-report questions. However, if
baseline dementia is subsequently identified dur-
ing baseline assessment via any of the processes
below, participants will be retrospectively cen-
sored as they cannot meet the definition of
incident dementia.
• Dementia is assumed if there is any self-reported
dementia to MYB via the medical history ques-
tionnaire (diagnosis or dementia medications),
stated as a reason to withdraw from the trial, or
it is otherwise reported to MYB that dementia
has been confirmed by a medical professional.
• If there is no self-report, dementia will be
assumed if linked data contain any of the fol-
lowing:
◦ Pharmaceutical Benefits Scheme (PBS)
claims for dispensing of Alzheimer’s dis-
ease medications (donepezil, galantamine,
or rivastigmine or memantine).
◦ Dementia listed as a diagnosis in hospital
records.
◦ Dementia listed as a cause of death in mor-
tality records.
• If none of the above indicates dementia, DSM-5
criteria [47] requiring cognitive impairment and
functional impairment will be applied.
◦ Cognitive impairment is measured by the
MYB Battery and an additional auto-
mated telephone-based verbal memory test
(LOGOS), developed and validated for
MYB.
◦ Cognitive impairment is defined as ≥2 SD
below the mean of the baseline sample on
any individual test (stratified for age, sex,
education) OR ≥1.5 SD below the mean of
the baseline sample in ≥1 domain. (strati-
fied for age, sex, education).
◦ Functional impairment is defined by the
Amsterdam-Instrumental Activity of Daily
Living-Short Form (A-IADL-SF; cut-off is
less than 51.4 [48]).
• If there are no cognitive data, dementia will be
“undetermined”.
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• If there is evidence for cognitive impairment
(defined above) but no data on function, partic-
ipants will be classified as “impaired cognition,
function undetermined”.
Secondary outcomes related to the overall impact
of the intervention and participant experience are: 1)
service utilization identified through routinely col-
lected linked data: hospital admissions, emergency
department presentations, medical and social care
services, and prescribed medications; 2) costs of pro-
gram as determined by quality adjusted life years
(QALYs) based on MYB used resources (e.g., staff
time) and intervention effect; 3) change in module
expectations as measured by the Module Expecta-
tions questionnaire (total; adapted from Rabipour &
Davidson [49]); 4) compliance with the intervention
and for each module undertaken (percentage activi-
ties complete and accessed per module; MYB digital
platform login data); and 5) number of adverse events
reported to MYB via the medical history and medical
events forms. Events include hospitalizations, muscle
soreness and food allergies.
Secondary outcomes related to risk factors targeted
by the four module interventions are: 1) change in
waist circumference and BMI if overweight/obese
(self-report in MYB Physical Activity questionnaire);
2) change in level of physical activity (HAQ energy
expenditure, stair climbing, walking. IPAQ sitting
time and volume and intensity of aerobic exercise,
resistance training, and balance exercise/week); 3)
new chronic conditions (count based on medical his-
tory and medical events forms); 4) change in physical
functional performance during the PA module as
measured by the virtual Short Physical Performance
Battery Score; 5) change in adherence to the Mediter-
ranean diet (MediCul score and derived MEDAS
score); 6) change in exposure to foods/culinary prac-
tices assessed via MediCul; 7) change in alcohol
(self-report in ADRI-SF and MediCul) and smoking
status (self-report in ADRI-SF); 8) change in within
task cognitive training performance in the Brain
Training module (percentage correct per session);
9) change in mental activity levels (LEQ late-life
subscale); 10) engagement during Brain Training
module (count use of social platform); and 11) change
from baseline to three years in psychological distress
(K10).
Data management
Electronic files collected by MYB that are not
linked data will be stored on a secure server. The des-
ignated MYB data custodian (MYB Data Manager)
will be responsible for maintaining data security and
assigning access controls. MYB has implemented
a role-based access mechanism that controls the
access to research data. The MYB platform can allow
authorized researchers, responsible for the day-to-
day running of the trial, to access information needed
for tasks such as responding to participant enquiries,
while ensuring trial-wide clinical data are not acces-
sible through the same pathway.
Assessments and linked data
MYB assessments to be completed by all partici-
pants (self-report), module specific assessments and
data sources for linked health data are summarized
in Table 1. Medicare Benefits Schedule (MBS) and
Pharmaceutical Benefits Scheme (PBS) data will be
accessed from the Department of Human Services
(DHS) and linkage completed by the Sax Institute
using a unique identifier that was provided by DHS.
Other linkage data (Table 1) will be performed by
the Centre for Health Record Linkage (CHeReL,
www.cherel.org.au) using probabilistic record link-
age techniques and ChoiceMaker software.
Statistics
Sample size
We will have 80% power to detect significant group
by time interaction in the MYB Battery primary out-
come, assuming linear change and a final difference
of 0.1 SD if we have 1,714 people in each group
(total N = 3,428) with type 1 error rate of 0.05. This
assumes a within-subjects correlation of 0.6 and a
Lear deterioration rate of 0.1. If we assume a 20%
drop out rate over the trial, we will need to recruit
at least 2,143 people in each arm. With 2,143 par-
ticipants per arm (4,285 in total), we will also have
80% power to detect differences of at least 0.1 SD for
continuous secondary outcomes.
Sample size estimates were obtained using
GLIMMPSE 2.0.0 [50] and G*Power 3.1 [51]. MYB
has the capacity to enroll up to 16,000 persons if it is
oversubscribed.
Analysis
Participants with at least two unique risk fac-
tors and eligibility for two modules or more will
be included in the MYB analysis. The trial will be
reported in accordance with the CONSORT guide-
lines. We will analyze all outcomes by the arm to
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Table 1
MYB assessments and timing of administration
Assessment/data source Measures Timing
MYB Eligibility 1a Trial eligibility Screening only
ANU-ADRI SF Dementia risk Baseline and annual follow-up
MYB Batteryb Cognitive ability Baseline, every 3 months in the first 12
months and then annually
LOGOSc Verbal memory Baseline, every 3 months in the first 12
months and then annually
Medical History Baseline Medical history Baseline only
Medical History Follow-up Medical history Annual follow-up
Physical Assessment batteryd Body composition, physical
activity, sitting time and
functional mobility performance
Baseline and annual follow-up
MediCul and derived MEDASe Dietary pattern Baseline and annual follow-up
Wellbeingf Psychological distress,
depression and anxiety
Baseline and annual follow-up
LEQ Cognitive lifestyle Baseline only
LEQ– Late life Late life subscale of LEQ Annual follow-up
A-IADL SF g Daily function Baseline and annual follow-up
Module Expectations Module expectations Pre/post modules only
Medical Events form Adverse events Every 3 months
Short Physical Activity measure (HAQ) Weekly physical activity Intervention Physical Activity module only -
module baseline and weekly during the
module; monthly during follow-up
MiniCul, weight and waist circumference Weekly nutrition Intervention Nutrition module only - module
baseline and weekly during the module;
monthly during follow-up
K10 Psychological distress Intervention Peace of Mind module only -
start of each lesson (6 over 10 weeks)
PHQ-9 Depression Intervention Peace of Mind module only -
start of lessons 1, 4 and 6
GAD-7 Anxiety Intervention Peace of Mind module only -
start of lessons 1, 4 and 6
Medicare Benefits Schedule (MBS)h Primary health care service use Available data at baseline to follow-up
Pharmaceutical Benefits Scheme (PBS)h Prescribed medicines Available data at baseline to follow-up
NSW Admitted Patient Data Collection (APDC)h Hospital use Available data at baseline to follow-up
NSW Emergency Department Data Collection
(EDDC)h
Emergency department
admissions
Available data at baseline to follow-up
NSW RBDM Death Registrationsh Deaths Available data at baseline to follow-up
Cause of Death Unit Record File (COD URF)h Deaths Available data at baseline to follow-up
NSW Mental Health Ambulatory Data Collectionh Service utilization Available data at baseline to follow-up
ANU-ADRI SF, ANU Alzheimer’s Disease Risk Index Short Form [18]; A-IADl-SF, Amsterdam IADL Questionnaire Short Form [48];
LEQ, Lifetime of Experiences Questionnaire [28]; K10, Kessler Psychological Distress Scale [45]; GAD-7, Generalized Anxiety Disorder
7-item [27]; PHQ9, Patient Health Questionnaire [15]. aMYB Eligibility 1 includes baseline Patient Health Questionnaire (PHQ-9). bThe
MYB Battery comprises tasks from the Cogstate Brief Battery (Detection, Identification, One Card and One Back) and Cambridge Brain
Sciences (Spatial (Tokens) Search, Grammatical Reasoning and Paired Associates). cLOGOS: an automated telephone-based test of episodic
verbal memory developed and validated for MYB. dThe Physical Assessment battery includes measures of body composition (self-reported
standing height, body mass, waist circumference); physical activity (the Harvard Alumni Questionnaire, HAQ [20]); sitting time (item from
the International Physical Activity Questionnaire, IPAQ [21]); and a measure of functional mobility and performance (the Virtual Short
Physical Performance Battery Protocol, vSPPB [22]). eAdherence to the Mediterranean dietary patterns include MediCul (Mediterranean
Diet and Culinary Index) [23]) and MEDAS (Mediterranean Diet Adherence Screener [24]). f Wellbeing assessment includes the Generalized
Anxiety Disorder 7-item (GAD-7), PHQ-9a, and Kessler Psychological Distress Scale (K10). gA-IADL-SF to be completed by an informant
for all participants (non-compulsory assessment). hLinked data.
which participants were allocated (i.e., intention to
treat analyses). We will analyze the primary outcome,
change in cognition, using linear mixed models to
examine the treatment group by time interaction and
will obtain a test of the difference between the groups
at the end of the trial. We will also conduct anal-
yses adjusting for baseline demographic variables;
additional adjustment for differential expectations
between arms or modules will be applied as neces-
sary. In addition, we will conduct subgroup analyses
on the primary outcome to determine if there is effect
modification by the number of risk factors at baseline
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(3 or 4 risk factors versus 2 risk factors). We expect
change in cognition to show a normal distribution.
However, if there are violations of the assumptions of
linear mixed models, appropriate transformations or
a generalized linear mixed model with an appropriate
distribution will be used.
Secondary outcomes will be analyzed using linear
mixed models for continuous normally distributed
outcomes or chi-squared tests for categorical out-
comes. We will use nonparametric tests for analyzing
continuous outcomes if the assumption of normality
is violated.
Safety
Data safety and monitoring board (DSMB)
A DSMB will be convened for this trial. It is
an independent group of experts that advises MYB
investigators. No member of the DSMB will have
direct involvement in the conduct of the study;
financial, proprietary, professional, or other interests
that may affect independent decision-making by the
DSMB.
Adverse event and serious adverse events
All MYB participants will be routinely logging
into the MYB platform (both control and intervention
group) for trial procedures. During these, they will
be prompted every 3 months by an on-screen ‘pop-
up’ to report any adverse event(s) in both a check
box and text box format, which will be followed by
specific advice to continue/start exercises or dietary
changes or not, or to see their health care provider
if indicated. All participants can also report adverse
events at any time of the trial (ad hoc reporting).
Adverse events during the Physical Activity and/or
Nutrition modules that are potentially related to the
interventions (e.g., muscles soreness, bloating) will
be proactively defined via factsheets and instructions
within each module, and recorded by the participants
on the web interface as they occur. These logged
events will be triaged by the Physical Activity and/or
Nutrition module leader and trainers as appropriate
for follow-up, referral to GP or study physicians, or
reporting to ethics.
A serious adverse event (SAE) is death, a life-
threatening adverse event, inpatient hospitalization or
prolongation of existing hospitalization, a persistent
or significant incapacity or substantial disruption of
the ability to conduct normal life functions. All SAEs
will be reported to the relevant ethics committees for
this trial.
Ethics
All trial procedures have been approved by the
University of New South Wales Human Research
Ethics Committee (#16252) and NSW Population and
Health Services Ethics Committee (#2016/03/636).
The conduct of the 45 and Up Study was approved by
the University of New South Wales Human Research
Ethics Committee (HREC).
DISCUSSION
Maintain Your Brain targets known modifiable
cognitive decline and dementia risk factors through
a personalized, multimodal online intervention. The
expected benefits of this approach are that MYB
has the capacity to target a number of risks in a
large number of participants. A range of modifi-
able risk factors for Alzheimer’s disease and vascular
dementia including vascular, cognitive, lifestyle, and
psychosocial factors, account for up to one third of the
population attributable risk for Alzheimer’s disease
[52] and are major risk factors for vascular dementia.
In Australia, there is an even higher estimated pop-
ulation attributable risk for dementia of 48% owing
to the distribution of these risk factors in the Aus-
tralian population [53]. Should Maintain Your Brain
be successful in addressing cognitive decline by tar-
geting multiple risk factors, it could provide a model
for interventions suitable for use in the broader com-
munity.
TRIAL STATUS
The MYB trial (Protocol v1.29, 03/05/18) plans to
recruit from June to October 2018.
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